125 related articles for article (PubMed ID: 28052682)
21. Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma.
Shim HS; Yoon BS; Cho NH
Hum Pathol; 2009 May; 40(5):693-8. PubMed ID: 19157508
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
23. Immunoexpression of E-, P- and N-cadherins in ovarian serous malignant tumors.
Dochiţ CM; Stepan AE; Mărgăritescu C; Florescu MM; Simionescu CE
Rom J Morphol Embryol; 2019; 60(4):1215-1219. PubMed ID: 32239097
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms.
Cho EY; Choi Y; Chae SW; Sohn JH; Ahn GH
Pathol Int; 2006 Feb; 56(2):62-70. PubMed ID: 16445817
[TBL] [Abstract][Full Text] [Related]
25. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
26. Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma.
Ho CM; Cheng WF; Lin MC; Chen TC; Huang SH; Liu FS; Chien CC; Yu MH; Wang TY; Hsieh CY
Int J Gynecol Cancer; 2010 Dec; 20(9):1490-7. PubMed ID: 21119364
[TBL] [Abstract][Full Text] [Related]
27. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R
Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
Cheng JC; Auersperg N; Leung PC
Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462
[TBL] [Abstract][Full Text] [Related]
29. Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.
Dettmar L; Ahmed N; Kotzsch M; Diersch S; Napieralski R; Darmoul D; Schmitt M; Weichert W; Kiechle M; Dorn J; Magdolen V
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1109-1118. PubMed ID: 29546479
[TBL] [Abstract][Full Text] [Related]
30. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
[TBL] [Abstract][Full Text] [Related]
31. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
[TBL] [Abstract][Full Text] [Related]
32. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
33. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
34. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
35. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases.
Daraï E; Scoazec JY; Walker-Combrouze F; Mlika-Cabanne N; Feldmann G; Madelenat P; Potet F
Hum Pathol; 1997 Aug; 28(8):922-8. PubMed ID: 9269828
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features.
Ferreira C; Lobo J; Antunes L; Lopes P; Jerónimo C; Henrique R
Virchows Arch; 2018 Oct; 473(4):443-452. PubMed ID: 30006753
[TBL] [Abstract][Full Text] [Related]
37. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
38. E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis.
Dian D; Brüning A; Mylonas I
Arch Gynecol Obstet; 2011 Aug; 284(2):437-43. PubMed ID: 20803206
[TBL] [Abstract][Full Text] [Related]
39. Roles of E-cadherin and cyclooxygenase enzymes in predicting different survival patterns of optimally cytoreduced serous ovarian cancer patients.
Taşkin S; Dünder I; Erol E; Taşkin EA; Kiremitçi S; Öztuna D; Sertçelik A
Asian Pac J Cancer Prev; 2012; 13(11):5715-9. PubMed ID: 23317244
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer.
Paik ES; Kim JH; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
J Gynecol Oncol; 2018 Jan; 29(1):e13. PubMed ID: 29185271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
